$VERX

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

Original reporting
Published Aug 5, 2026, 9:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:55 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vertex Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$VERXBullishMed
01

Why it matters

Key trading inputs are the raised full-year adjusted EBITDA range, the 18% full-year cloud revenue growth expectation, and management’s explanation that slower cloud conversion is timing-related rather than customer loss. E-invoicing is positioned to start affecting ARR in Q3 and ramp more in Q4 as transaction volumes increase.

02

Market read

Guidance and forward-looking ARR timing for e-invoicing versus cloud-conversion delays are the main catalysts for near-term positioning.

03

What to watch

Free cash flow was low ($2.7M) due to severance and consulting costs, which could matter for valuation even with pro forma FCF improvement.

Relevance 8/10Novelty 7/10Timing: pre-market guidance update for Q3 and full-year

Background

The piece summarizes Vertex’s Q2 earnings call, focusing on cloud conversion pace, e-invoicing momentum, AI initiatives, and updated financial guidance.

Company-level read

Ticker impact

$VERXBullishMedium confidence
Context

Vertex guided Q3 revenue to $208M-$211M and raised full-year adjusted EBITDA to $206M-$210M, plus expects full-year cloud growth of 18%.

Expected impact

Likely supportive for the stock on guidance raise, with follow-through dependent on whether investors focus on cloud-conversion timing versus e-invoicing ramp.

Evidence & confidence

The article discloses multiple forward-looking guidance datapoints (Q3 and full-year) and management commentary explaining cloud timing as non-loss of customers, which typically drives a net positive read but can cap upside if cloud conversion is viewed as a demand issue.

Market effects

Highlights ongoing European e-invoicing mandate tailwinds and AI-enabled compliance tooling as demand drivers for tax software providers.

France and Germany mandate progress is explicitly tied to e-invoicing wins and expected ARR impact timing.

Mandate-driven compliance expansion is framed as potentially expanding country-by-country into broader provider consolidation.

Counterpoint

Investors may discount the EBITDA raise if cloud-conversion delays persist, making the e-invoicing ARR timing (Q3 impact, larger Q4 ramp) the only near-term lever.

Key entities

  • Vertex

    Discussed Q2 execution across cloud conversion, e-invoicing wins, AI productivity initiatives, and provided Q3 and full-year guidance.

  • John Schwab

    CFO who commented on cloud-conversion timing and e-invoicing ARR impact expectations.

  • Young

    Management speaker who described mixed customer environments and AI/product roadmap emphasis.

Related articles

$VERXMedAI 8/10

Vertex (VERX) Q2 2026 Earnings Call Transcript

Vertex, Inc. (VERX) reported Q2 2026 revenue of $204 million, up 10.5% year over year and at the high end of guidance. Adjusted EBITDA rose 33% to $51 million, with margin expanding to 25.0%. Subscription revenue grew to $174.8 million and ARR reached $703.4 million. Full-year revenue guidance was narrowed to $825-$830 million and adjusted EBITDA guidance raised to $206-$210 million.

$VERXMedAI 8/10

Vertex Raises Profit Outlook as Cloud Revenue Climbs 18%

Vertex (NASDAQ: VERX) raised its 2026 adjusted EBITDA outlook to $206M-$210M after Q2 revenue rose 10.5% to $204M and cloud revenue grew 17.9% to $101.7M. Full-year revenue guidance was narrowed to $825M-$830M, with 18% cloud growth expected. Q2 adjusted EBITDA rose 32.8% to $51M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.